Study of FLT3 gene changes in AML patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial looks at people with acute myeloid leukemia (AML) who have a change in a gene called FLT3. It aims to understand how this change affects the disease and how well treatments work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with acute myeloid leukemia (AML)
- Your AML must have a mutation (change) in the FLT3 gene
- You must not have already responded to treatment for AML
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.
This trial tests a targeted therapy for people with a specific genetic change in their AML cells called FLT3-ITD. It aims to see if adding this targeted drug to standard chemotherapy improves outcomes for patients who are otherwise healthy enough to receive intensive treatment.
This Phase 3 study compares HEC73543 versus standard “salvage” chemotherapy in adults with AML that has come back or did not respond after first treatment. It’s designed for people whose leukemia has an FLT3-ITD mutation and may help improve response and outcomes.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
Hear when a new Myeloid Leukemia, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.